Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American heart association, American cancer society, and American urological association: Endorsed by the American society for radiation oncology

CA Cancer Journal for Clinicians

Volumn 60, Issue 3, 2010, Pages 194-201

  Levine, Glenn N ^a   D'Amico, Anthony V ^b   Berger, Peter ^c   Clark, Peter E ^d   Eckel, Robert H ^e   Keating, Nancy L ^f   Milani, Richard V ^g   Sagalowsky, Arthur I ^h   Smith, Matthew R ⁱ   Zakai, Neil ^j  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g OCHSNER CLINIC FOUNDATION   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF VERMONT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSULTATION; DYSLIPIDEMIA; EXTERNAL BEAM RADIOTHERAPY; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; CHEMICALLY INDUCED DISORDER; MALE; PROSTATE TUMOR; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; MALE; MORBIDITY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 77952568266     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20061     Document Type: Article

References (43)

1. Keating NL, O'Malley AJ, Smith MR. Diabetesandcardiovasculardiseaseduringandrogen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-4456.
2. Saigal CS, Gore JL, Krupski TL, et al; and the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493-1500.
3. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420-2425.
4. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516-1524.
5. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrentprostatecancer. Cancer.2008;113: 3290-3297.
6. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol. 2004;92:287-295.
7. Paulson DF. Management of metastatic prostatic cancer. Urology. 1985;25(suppl): 49-52.
8. Bolla M, Collette L, Blank L, et al. Longterm results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-106.
9. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497-2504.
10. Denham JW, Steigler A, Lamb DS, et al. Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the TransTasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841-850.
11. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289-295.
12. Roach M III, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585-591.
13. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-1290.
14. Moul JW, Bañez LL, Freedland SJ. Rising PSAinnonmetastaticprostatecancer.Oncology (Williston Park). 2007;21:1436-1445.
15. Wang H, Wallner K, Sutlief S, et al. Transperineal brachytherapy in patients with large prostate glands. Int J Cancer. 2000;90: 199-205.
16. Tayek JA, Heber D, Byerley LO, et al. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism. 1990; 39:1314-1319.
17. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261-4267.
18. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87: 599-603.
19. Berruti A, Dogliotti L, Terrone C, et al. Gruppo Onco Urologico Piemontese (G.O.U.P.), Rete Oncologica Piemontese. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361-2367.
20. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63: 742-745.
21. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropinreleasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112: 2188-2194.
22. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and longterm gonadotropin releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005;104:1633-1637.
23. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol. 1995;154:100-104.
24. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305-1308.
25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(suppl):S55-S60.
26. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
27. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998;98:398-404.
28. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104: 195-201.
29. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365: 1415-1428.
30. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgendeprivation therapy. J Clin Oncol. 2006;24: 3979-3983.
31. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318-322.
32. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008;54:816-823.
33. Efstathiou J, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27:92-99.
34. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27:3452-3458.
35. Bolla M, de Reijke TM, Van Tienhoven G, et al. EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516-2527.
36. Nanda AN, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302:866-873.
37. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24:1868-1876.
38. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 up-date [published correction appears in Circulation. 2006;113:e847]. Circulation. 2006; 113:2363-2372.
39. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(suppl):S12-S54.
40. Grundy SM, Cleeman JI, Merz CN, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation 2004;110:763]. Circulation. 110:227-239, 2004.
41. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
42. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290: 197]. JAMA. 2003;289:2560-2572.
43. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American HeartAssociationTaskForceonRiskReduction. Circulation. 1997;96:3243-3247.